Is trastuzumab associated with adverse cardiac effects in patients with breast cancer?: Commentary

Nature Clinical Practice Oncology

Volumn 5, Issue 4, 2008, Pages 192-193

  Ewer, Michael S ^a   Lenihan, Daniel J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; TRASTUZUMAB; TROPONIN;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; HEART DEATH; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT DURATION;

EID: 41849095956     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1045     Document Type: Short Survey

References (5)

1. Ewer MS and Lippman SM (2005) Type II chemotherapy related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23 2900-2902
2. Ewer MS et al. (2005) Reversibility of trastuzumabrelated cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820-7826
3. Lenihan DJ et al. (2007) Superior detection of cardiotoxicity during chemotherapy using biomarkers. J Card Failure 13: S151
4. Cardinale D et al. (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109: 2749-2754
5. Kalay N et al. (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48: 2258-2262